167 results
6-K
ASND
Ascendis Pharma A/S
2 May 24
Current report (foreign)
4:29pm
, and conducting preclinical studies and clinical trials;
our pursuit of oncology as our second independent therapeutic area of focus and our development … independent as a profitable biopharma through lean and flexible ways of working
oLet our values Patients, Science, Passion drive our decisions to success
Our
6-K
EX-99.1
ASND
Ascendis Pharma A/S
2 May 24
Ascendis Pharma Reports First Quarter 2024 Financial Results
4:22pm
are in place to deliver three independent Endocrinology Rare Disease blockbuster products and a strong pipeline in larger therapeutic areas such as Oncology … ’ expectations regarding full year 2024 revenue for SKYTROFA, (v) Ascendis’ ability to fulfill its strategic goals to deliver three independent
6-K
EX-99.2
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
Contents
Company Information
Statement by Management on the Annual Report
Independent Auditor’s Report
Management Commentary
Statements of Profit …
Independent Auditor’s Report
To the shareholders of Ascendis Pharma A/S
Opinion
We have audited the consolidated financial statements and the parent
6-K
EX-99.3
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
. Grants are provided for medical and scientific research, independent education, fellowships and collaborative studies, while our donations focus
6-K
EX-1.1
ASND
Ascendis Pharma A/S
10 Apr 24
Current report (foreign)
4:02pm
a nationally recognized independent investment banking firm selected by the Company, which may include any of the Initial Purchasers. The Last Reported Sale … on the accuracy of the Company’s calculations without independent verification. The Trustee will promptly forward a copy of each such schedule to a Holder
6-K
EX-1.1
5zztlhhiog822xx9j
27 Mar 24
Current report (foreign)
4:01pm
6-K
EX-1.1
2w37wksd ymtyv704i
14 Mar 24
Current report (foreign)
4:05pm
S-8
ivcvzs9weo5akirpbg
29 Feb 24
Registration of securities for employees
4:29pm
S-8
EX-23.1
22vg2bv36q2yp7 q6
29 Feb 24
Registration of securities for employees
4:29pm
6-K
EX-1.1
rppx091uchak5
14 Feb 24
Current report (foreign)
4:07pm
6-K
EX-99.1
9daisgf
7 Feb 24
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
4:05pm
6-K
EX-1.1
8kf777r
10 Jan 24
Current report (foreign)
4:02pm
6-K
EX-99.1
v1kp1lu5d0sorb7b7
8 Jan 24
Current report (foreign)
6:08am
6-K
qj0uoa8in2qoo0
8 Jan 24
Current report (foreign)
6:05am